ARVN
ARVN clinical trials: ARVINAS, INC.
Every trial on ClinicalTrials.gov where ARVINAS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 5
- Trials linked
- 5
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ARVN on the catalyst calendar · ARVN registry changes
- Primary completion Mar 31, 2031Sponsor estimatePhase 1/Phase 2NCT07749586A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsArvinas Inc. · Advanced Solid TumorRecruitingARVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2026ActualPhase 1/Phase 2NCT07023731A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D MutationArvinas Inc. · KRAS G12D MutationCompletedARVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2028Sponsor estimatePhase 1NCT06393738A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.Arvinas Inc. · Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)RecruitingARVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 13, 2024ActualPhase 2NCT05549505A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryArvinas Inc. · Breast CancerCompletedARVNLeadPFECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 29, 2024ActualPhase 1/Phase 2NCT03888612Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate CancerArvinas Inc. · Prostate Cancer MetastaticCompletedARVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 5 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner